	US 12,186,318 B2
	Pharmaceutical composition for preventing or treating cancer comprising KSP inhibitor and mitosis inhibitor
Hyung Jun Ahn, Seoul (KR)
Assigned to KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, Seoul (KR)
Filed by KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, Seoul (KR)
Filed on Oct. 29, 2020, as Appl. No. 17/083,895.
Claims priority of application No. 10-2020-0023032 (KR), filed on Feb. 25, 2020.
Prior Publication US 2021/0260063 A1, Aug. 26, 2021
Int. Cl. A61K 31/517 (2006.01); A61K 31/337 (2006.01); A61K 31/404 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01)

CPC A61K 31/517 (2013.01) [A61K 31/337 (2013.01); A61K 31/404 (2013.01); C12N 15/113 (2013.01); A61K 45/06 (2013.01)]

5 Claims

1. A method of treating a cancer, the method comprising administering a pharmaceutical composition to an individual suspected to have the cancer in a pharmaceutically effective amount,

wherein the pharmaceutical composition comprises a PEGylated liposome, which comprises kinesin spindle protein (KSP) short interfering RNA (siRNA), and a paclitaxel,

wherein the method simultaneously inhibits expression of KSP and a substitution effect of Kif15 for KSP, by treating kinesin spindle protein (KSP) short interfering RNA (siRNA) and a paclitaxel simultaneously.